Article
TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo.
Neuro-oncology - 1 Dec 2022
Miki Shunichiro, Koga Tomoyuki, Mckinney Andrew M, Parisian Alison D, Tadokoro Takahiro, Vadla Raghavendra, Marsala Martin, Hevner Robert F, Costello Joseph F, Furnari Frank
Abstract excerpt
BACKGROUND: Heterozygous TERT (telomerase reverse transcriptase) promoter mutations (TPMs) facilitate TERT expression and are the most frequent mutation in glioblastoma (GBM). A recent analysis revealed this mutation is one of the earliest events in gliomagenesis. However, no appropriate human models have been engineered to study the role of this mutation in the initiation of these tumors. METHOD: We established...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.